Impact of sentinel node biopsy on long-term quality of life in breast cancer patients

6533b7d4fe1ef96bd1261f4d

RESEARCH PRODUCT

Impact of sentinel node biopsy on long-term quality of life in breast cancer patients

J-m Sauzedde Sebastien Gouy Charles Coutant M-m Padeano Christian Rosburger J-p Combier Patrick Chevillote Patrick Arveux A Guyomard E. De Gournay Tienhan Sandrine Dabakuyo-yonli J. Fraisse Sylvain Causeret Marc Smail Catherine Loustalot S. Boulet F. Bonnetain

subject

Cancer Research medicine.medical_specialty Time Factors Health Status Breast surgery medicine.medical_treatment Sentinel lymph node Breast Neoplasms breast cancer Breast cancer Quality of life Surveys and Questionnaires Body Image Humans Medicine Aged Sentinel Lymph Node Biopsy business.industry Carcinoma Ductal Breast Axillary Lymph Node Dissection Cancer Middle Aged Sentinel node medicine.disease humanities Surgery Lymphedema quality of life Oncology Clinical Study Lymph Node Excision Female Neoplasm Recurrence Local business Follow-Up Studies

description

Background: The aim of this study was to assess long-term quality of life (QoL) over a period of 6 years in women with breast cancer (BC) who underwent sentinel lymph node biopsy (SLNB), axillary lymph node dissection (ALND), or SLNB followed by ALND. Methods: The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ)-C30 and the EORTC-QLQ-BR-23 questionnaires were used to assess QoL before surgery, just after surgery, 6, 12 and 72 months later. The longitudinal effect of surgical modalities on QoL was assessed with a mixed model analysis of variance for repeated measurements. Results: Five hundred and eighteen BC patients were initially included. The median follow-up was 6 years. During the follow-up, 61 patients died. None of the patients of the SLNB group developed lymphedema during follow-up and the relapse rate was similar in the different groups (P=0.62). Before surgery, global health status (P=0.52) and arm symptoms (BRAS) (P=0.99) QoL scores were similar whatever the surgical procedure. The BRAS score (P=0.0001) was better in the SLNB group 72 months after surgery. Moreover, during follow-up, patients treated with SLNB had lower arm symptoms scores than ALND patients and there was no difference for arm symptoms between patients treated with ALND and those treated with SLNB followed by complementary ALND. Conclusion: Long-term follow-up showed that SLNB was associated with less morbidity than ALND.

year	journal	country	edition	language
2013-06-05	British Journal of Cancer

https://doi.org/10.1038/bjc.2013.658